News

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...
Clinical Advisor5h
FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid
The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.
Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials
The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...
The Community Voice2h
FDA Approves Novavax COVID-19 Shot with Restrictions
The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.
FDA may limit future Covid-19 shots to older people and those at risk of serious infection
The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit ...
New Trump vaccine policy might limit access to your future COVID shots: 10 points
The US Food and Drug Administration changes Covid-19 vaccine approval process. Access to seasonal boosters is restricted for ...
FDA sets new COVID booster guidelines for healthy adults under 65
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
BofA Reiterates Hold Rating on Novavax (NVAX) Stock
BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...
New Trump vaccine policy limits access to COVID shots
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...
FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups
WEDNESDAY May 21, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has decided that only seniors and ...